title: Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy.
abstract: OBJECTIVE
  To analyse the determinants of high blood pressure in women around menopause.
  
  
  METHODS
  Eligible women were consecutively identified among patients who asked for a visit of their general practitioner during the period March November 1997. A total of 22919 women aged 44-66 years (median age 55 years), were identified. Women whose mean of the second and third of the three measures of diastolic blood pressure values performed during interview was > 90 mm of mercury and/or reporting any type of current pharmacological treatment for elevated blood pressure were considered hypertensive.
  
  
  RESULTS
  In comparison with women aged 40-50 years, the multivariate odds ratio (OR) of elevated blood pressure were 1.4 in women aged 51-55, 2.0 in those aged 56-60 and 2.7 in those aged > or = 61. In comparison with women with a body mass index (kg m(-2)) < 25, the OR of elevated blood pressure was 1.7 and 2.7, respectively, for women with a BMI of 25 28 and > or = 29. In comparison with women reporting a low level of physical activity, the OR of elevated blood pressure were 0.9 (95%, confidence interval, CI 0.7-1.0) and 0.7 (95% CI 0.4-0.9), respectively, for those reporting an intermediate or high level of activity. In comparison with premenopausal women, the OR of elevated blood pressure was, after taking into account the confounding effect of age, 1.6 (95% CI 1.0-1.4) in post menopausal ones. The OR of elevated blood pressure was 0.8 (95% CI 0.7-0.9), for current users of hormone replacement therapy (HRT), but no clear association emerged with duration of HRT pressure.
  
  
  CONCLUSIONS
  This study suggests that, after taking into account the effect of age, post-menopausal women are at higher risk of the condition, and current HRT use decreases the risk. Other main determinants of risk of elevated blood pressure were overweight and low physical activity.
authors.affiliation: Medical Department, Bayer, Milan, Italy. sa1@bayer-ag.de
authors.forename: S
authors.initials: S
authors.lastname: Amigoni
authors.forename: P
authors.initials: P
authors.lastname: Morelli
authors.forename: F
authors.initials: F
authors.lastname: Parazzini
authors.forename: L
authors.initials: L
authors.lastname: Chatenoud
mesh_terms: D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D048909:Diabetes Complications; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000453:epidemiology* / Q000209:etiology; D015228:Hypertriglyceridemia / Q000150:complications; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D016017:Odds Ratio; D010809:Physical Fitness; D017698:Postmenopause; D015995:Prevalence; D012307:Risk Factors